Pharmafile Logo
Pharmafocus logo
Advanced Search

sickle cell disease

Showing 8 posts of 8 posts found.

EC approves Vertex’s Casgevy for sickle cell disease treatment

February 13, 2024
Medical Communications Casgevy, European Commission, Haematology, Vertex pharmaceuticals, sickle cell disease

Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a CRISPR/Cas9 …

News
bluebird_bio_external_durham_nc_manufacturing

FDA halts studies for bluebird bio’s sickle cell therapy LentiGlobin

February 24, 2021
Research and Development Bluebird Bio, FDA, sickle cell disease

The FDA has put bluebird bio’s LentiGlobin gene therapy programme for sickle cell disease (SCD) on clinical hold, following Suspected …

News

Novartis and Gates Foundation join forces on sickle cell disease research

February 17, 2021
Research and Development Novartis, sickle cell disease

Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation, under which the foundation will fund …

News
1911-sickle-cells

FDA approves GBT’s Oxbryta to treat sickle cell disease

November 26, 2019
Manufacturing and Production FDA, FDA Trump, Oxbryta, Sickle cell, sickle cell disease

The FDA announced yesterday that it has approved Global Blood Therapeutics’ marketing application for its haemoglobin polymerisation inhibitor Oxbryta, which …

News

Novartis’ Adakveo becomes first FDA-approved P-selectin inhibitor for sickle cell disease

November 18, 2019
Sales and Marketing Adakve, Novartis, pharma, sickle cell disease

The FDA has chosen to award Novartis’ Adakveo (crizanlizumab) with marketing authorisation, it has emerged, as a treatment to reduce …

News
novartis_outside_1

Novartis’ sickle cell drug reduces vaso-occlusive crises by 35% at Phase 2

October 10, 2018
Research and Development Novartis, crizanlizumab, pharma, sickle cell disease

Novartis has presented new Phase 2 data for its humanised anti-P-selectin monoclonal antibody crizanlizumab in the treatment of sickle cell …

News
sickle_cells

FDA gives go-ahead to first sickle cell treatment in 20 years

July 10, 2017
Sales and Marketing Emmaus Medical, L-glutamine, sickle cell disease

Emmaus Medical has been handed approval for the first new treatment for sickle cell disease in two decades. The active …

News
globalblood

Shares in Global Blood jump after positive results for trial sickle cell drug

June 13, 2016
Research and Development, Sales and Marketing Global Blood Therapeutics, drug trial, sickle cell disease

Global Blood Therapeutics (Nasdaq: GBT) shares jumped to close up over 9% Friday after the company said its trial drug …

News

Latest content

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024